OncoMatch

OncoMatch/Clinical Trials/NCT06585410

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Is NCT06585410 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Cemiplimab for cutaneous squamous cell carcinoma (cscc).

Phase 3RecruitingRegeneron PharmaceuticalsNCT06585410Data as of May 2026

Treatment: Cemiplimab — This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

adequate bone marrow function, as described in the protocol

Kidney function

adequate renal function, as described in the protocol

Liver function

adequate hepatic function, as described in the protocol

Adequate hepatic, renal and bone marrow functions, as described in the protocol

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Medical Dermatology Specialists · Phoenix, Arizona
  • Mayo Clinic - Arizona · Scottsdale, Arizona
  • University of Arizona Cancer Center · Tucson, Arizona
  • Arkansas Research Trials · North Little Rock, Arkansas
  • UC San Diego Moores Cancer Center · La Jolla, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify